Formoterol dry-powder inhalation - AstraZeneca

Drug Profile

Formoterol dry-powder inhalation - AstraZeneca

Alternative Names: Eformoterol dry-powder inhalation - AstraZeneca; Formoterol fumarate dry-powder inhalation - AstraZeneca; Formoterol Turbuhaler; Oxez Turbuhaler; Oxeze Turbuhaler; Oxis; Oxis Turbuhaler

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease; Exercise-induced asthma

Most Recent Events

  • 01 Dec 2016 AstraZeneca completes a phase II trial for Chronic obstructive pulmonary disease in USA (Inhalation) (NCT02796651)
  • 01 Jun 2016 Phase-III clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
  • 01 Jun 2016 AstraZeneca initiates a phase II trial for Chronic obstructive pulmonary disease in USA (Inhalation) (NCT02796651)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top